ReviewInternational journal of molecular sciences2026
Next-Generation Liposomal and Nanoparticle-Based Systems for Glioblastoma: Molecular Targeting Strategies to Overcome the Blood-Brain Barrier.
Review in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glioblastoma (GBM) remains one of the most lethal and intractable central nervous system malignancies, characterized by aggressive cellular proliferation, profound hypoxia, and an immunosuppressive microenvironment. The primary pharmacokinetic obstacle for systemic interventions is the blood-brain barrier (BBB), which restricts the infiltration of free therapeutic agents. To overcome this limitation, translational nanomedicine has driven the design of next-generation delivery systems, including liposomal vectors and synthetic organic, inorganic, and hybrid nanoparticles. This study establishes an exhaustive analysis of molecular targeting strategies designed to actively hijack physiological transport pathways via receptor-mediated transcytosis (RMT) targeting transferrin, lactoferrin, and LRP1 receptors and adsorption-mediated transcytosis (AMT) using polycationic biomaterials. Terminal selectivity via tumor-specific antigens, such as EGFRvIII and nucleolin (targeted by the AS1411 aptamer), is also discussed alongside smart stimuli-responsive platforms that exploit the tumor microenvironment's acidic pH, hypoxia, and matrix metalloproteinase activity for localized drug release. Concurrently, the deployment of these nanoplatforms for the intracellular vectorization of advanced genetic material, including siRNA (targeting VEGF and MGMT) and CRISPR/Cas9 complexes, demonstrates significant efficacy in reversing genomic chemoresistance and collapsing tumor neoangiogenesis. Finally, the review addresses critical bioengineering and clinical bottlenecks such as manufacturing scale-up, human BBB complexity, opsonization, and the long-term toxicity of inorganic nanoparticles that currently limit the regulatory transition of these highly promising neuro-oncological nanotechnologies from bench to bedside.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.